<DOC>
	<DOCNO>NCT01313507</DOCNO>
	<brief_summary>This prospective , open-label , non-controlled , non-randomized multicenter Phase III study 2 multiple-dose intravenous NewGam regimen ( every 3 week every 4 week , continue patient 's infusion interval main study NCT01012323 [ NGAM-01 ] ) 3 month . The primary objective study assess safety tolerability high infusion rate NewGam .</brief_summary>
	<brief_title>High Infusion Rate Study Immunoglobulin Intravenous ( Human ) 10 % ( NewGam )</brief_title>
	<detailed_description>Patients receive NewGam via infusion pump control precise infusion rate . All NewGam infusion start rate 0.01 mL/kg/min ( 60 mg/kg/h ) first 30 minute follow 0.03 mL/kg/min ( 180 mg/kg/h ) next 15 minute . If tolerate , increment make predefined pattern follow maximum rate : 0.10 mL/kg/min ( 600 mg/kg/h ) first infusion ; tolerate , 0.12 mL/kg/min ( 720 mg/kg/h ) second infusion ; tolerate , 0.14 mL/kg/min ( 840 mg/kg/h ) subsequent infusion . If adverse event occur infusion , rate reduce half rate event occur infusion interrupt symptom subside . The infusion resume rate tolerate patient .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Completion main study NGAM01 . At last 3 infusion main study NGAM01 , administration NewGam maximum infusion rate 0.08 mL/kg/min without need premedication . Any condition circumstance would lead exclusion subject NGAM01 study . Administration immunoglobulin infusion NewGam conclusion NGAM01 study begin present study . A deviation subject 's treatment interval 7 day last infusion NewGam NGAM01 study first infusion NewGam present study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Immunodeficiency Disease</keyword>
	<keyword>PID</keyword>
</DOC>